Genetic profile of non-small cell lung cancer (NSCLC): A hospital-based survey in Jinhua

被引:13
|
作者
Chen, Xianguo [1 ]
Xu, Bo [1 ]
Li, Qiang [2 ]
Xu, Xiaoyi [1 ]
Li, Xianshuai [1 ]
You, Xia [2 ]
Yu, Zhaonan [2 ]
机构
[1] Zhejiang Univ, Jinhua Hosp, Jinhua Municipal Cent Hosp, Dept Thorac Surg, Jinhua, Zhejiang, Peoples R China
[2] Hangzhou DA Med Lab, Hangzhou 310030, Peoples R China
来源
MOLECULAR GENETICS & GENOMIC MEDICINE | 2020年 / 8卷 / 09期
关键词
clinical characteristics; genetic profile; nonsmall cell lung cancer; targeted sequencing; DRIVER MUTATIONS; IASLC/ATS/ERS CLASSIFICATION; YOUNG-PATIENTS; ADENOCARCINOMA; ASSOCIATION; PREVALENCE; THERAPY; SMOKERS; EGFR;
D O I
10.1002/mgg3.1398
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: We describe the clinical features, genetic profile, and their correlation in NSCLC patients. Methods: A total of 256 Chinese patients with NSCLC were enrolled in this study. NGS-based genomic profiling of major lung cancer-related genes was performed on formalin-fixed paraffin-embedded tumor samples. Results: Of 256 patients with NSCLC, 219 were adenocarcinoma and most of them were in the early stage. Among patients, 63.3% patients have more than two gene mutations. By analyzing variant allele frequency (VAF), we found that the median VAF has significant differences between squamous cell carcinoma and adenocarcinoma, as well as early stage and advanced stage. The frequency of mutations in EGFR, MET, and RET were significantly higher in nonsmokers than in smokers. Besides, Pearson correlation analysis found that ALK, BRAF, and MET mutations had a strong correlation with age. Notably, higher frequencies of ALK and BRAF alterations were associated with younger age, while more frequent MET mutations appear in the patients at age 55 or older. Conclusion: More unique features of cancer driver genes in Chinese NSCLC were identified by next-generation sequencing. These findings highlighted that it is necessary to carry out targeted detection according to different clinical features for NSCLC.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Computed tomography imaging of non-small cell lung cancer
    Chassagnon, G.
    Bennani, S.
    Revel, M. P.
    CANCER RADIOTHERAPIE, 2016, 20 (6-7): : 694 - 698
  • [42] Individualized therapy in the adjuvant setting for non-small cell lung cancer (NSCLC)
    Mascaux, Celine
    Ekman, Simon
    Dooms, Christophe
    Shepherd, Frances A.
    CURRENT PULMONOLOGY REPORTS, 2013, 2 (01) : 1 - 9
  • [43] Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC)
    Schmid-Bindert, Gerald
    TARGETED ONCOLOGY, 2013, 8 (01) : 15 - 26
  • [44] Identification and validation of the methylation biomarkers of non-small cell lung cancer (NSCLC)
    Shicheng Guo
    Fengyang Yan
    Jibin Xu
    Yang Bao
    Ji Zhu
    Xiaotian Wang
    Junjie Wu
    Yi Li
    Weilin Pu
    Yan Liu
    Zhengwen Jiang
    Yanyun Ma
    Xiaofeng Chen
    Momiao Xiong
    Li Jin
    Jiucun Wang
    Clinical Epigenetics, 2015, 7
  • [45] Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC)
    Fumihiro Tanaka
    Kazue Yoneda
    Surgery Today, 2016, 46 : 25 - 37
  • [46] Concomitant hypermethylation of multiple genes in non-small cell lung cancer (NSCLC)
    Ji, Meiju
    Guan, Haixia
    Shi, Bingyin
    Hou, Peng
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2011, 49 (01) : 132 - 141
  • [47] Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC)
    Bodor, J. Nicholas
    Boumber, Yanis
    Borghaei, Hossein
    CANCER, 2020, 126 (02) : 260 - 270
  • [48] Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC)
    Tanaka, Fumihiro
    Yoneda, Kazue
    SURGERY TODAY, 2016, 46 (01) : 25 - 37
  • [49] Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC)
    Klastersky, Jean
    Awada, Ahmad
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 81 (01) : 49 - 57
  • [50] Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness
    Terlizzi, Michela
    Colarusso, Chiara
    Pinto, Aldo
    Sorrentino, Rosalinda
    PHARMACOLOGY & THERAPEUTICS, 2019, 202 : 140 - 148